Zeke Capital Advisors LLC grew its stake in Bio-Techne (NASDAQ:TECH) by 34.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,265 shares of the biotechnology company’s stock after purchasing an additional 3,395 shares during the quarter. Zeke Capital Advisors LLC’s holdings in Bio-Techne were worth $1,718,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Financial Gravity Companies Inc. acquired a new stake in shares of Bio-Techne in the fourth quarter valued at about $118,000. Advisory Services Network LLC lifted its stake in shares of Bio-Techne by 1,423.3% in the fourth quarter. Advisory Services Network LLC now owns 1,112 shares of the biotechnology company’s stock worth $144,000 after buying an additional 1,039 shares in the last quarter. Advisor Group Inc. lifted its stake in shares of Bio-Techne by 64.5% in the fourth quarter. Advisor Group Inc. now owns 1,288 shares of the biotechnology company’s stock worth $167,000 after buying an additional 505 shares in the last quarter. Zions Bancorporation purchased a new position in shares of Bio-Techne in the third quarter worth about $178,000. Finally, Gofen & Glossberg LLC IL purchased a new position in shares of Bio-Techne in the fourth quarter worth about $205,000. Institutional investors and hedge funds own 97.12% of the company’s stock.
Shares of TECH stock opened at $145.33 on Friday. The company has a current ratio of 3.10, a quick ratio of 2.49 and a debt-to-equity ratio of 0.36. Bio-Techne has a 12 month low of $98.35 and a 12 month high of $151.89. The stock has a market cap of $5,516.92, a price-to-earnings ratio of 42.49, a PEG ratio of 2.82 and a beta of 0.70.
Bio-Techne (NASDAQ:TECH) last issued its earnings results on Tuesday, February 6th. The biotechnology company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.10. Bio-Techne had a net margin of 19.17% and a return on equity of 14.39%. The company had revenue of $154.15 million for the quarter, compared to the consensus estimate of $145.93 million. During the same period in the previous year, the firm earned $0.81 earnings per share. Bio-Techne’s quarterly revenue was up 16.9% compared to the same quarter last year. research analysts anticipate that Bio-Techne will post 4.01 EPS for the current fiscal year.
In other Bio-Techne news, Director Charles A. Dinarello sold 5,000 shares of Bio-Techne stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $136.06, for a total transaction of $680,300.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.40% of the stock is owned by insiders.
Several equities analysts have recently weighed in on TECH shares. Zacks Investment Research downgraded shares of Bio-Techne from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. BidaskClub raised shares of Bio-Techne from a “hold” rating to a “buy” rating in a research note on Wednesday, January 10th. Deutsche Bank set a $163.00 price target on shares of Bio-Techne and gave the stock a “buy” rating in a research note on Thursday, March 1st. Robert W. Baird reissued a “buy” rating and issued a $154.00 price target on shares of Bio-Techne in a research note on Thursday, January 18th. Finally, Craig Hallum reissued a “buy” rating and issued a $160.00 price target (up from $140.00) on shares of Bio-Techne in a research note on Wednesday, February 7th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Bio-Techne has an average rating of “Buy” and a consensus price target of $148.60.
TRADEMARK VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/bio-techne-corp-tech-holdings-boosted-by-zeke-capital-advisors-llc.html.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.